Bryan S Benn1, Zoe Lehman1, Sharon A Kidd1, Melissa Ho1, Sara Sun1, Joris Ramstein1, Nicholas K Arger1, Christine P Nguyen1, Robert Su2, Antonio Gomez3, Jeffrey M Gelfand4, Laura L Koth5. 1. Division of Pulmonary and Critical Care, University of California, San Francisco, San Francisco, CA, 94143, USA. 2. Palo Alto Medical Foundation, Palo Alto, CA, USA. 3. Division of Pulmonary and Critical Care Medicine, Zuckerberg San Francisco General Hospital & Trauma Center, San Francisco, CA, USA. 4. Department of Neurology, Multiple Sclerosis and Neuroinflammation Center, University of California, San Francisco, San Francisco, CA, USA. 5. Division of Pulmonary and Critical Care, University of California, San Francisco, San Francisco, CA, 94143, USA. laura.koth@ucsf.edu.
Abstract
INTRODUCTION: Sarcoidosis is a systemic inflammatory disease characterized by non-necrotizing granulomas in involved organs, most commonly the lung. Description of patient characteristics in the Western United States is limited. Furthermore, blood-based measures that relate to clinical sarcoidosis phenotypes are lacking. We present an analysis of a prospective, longitudinal sarcoidosis cohort at a Northern Californian academic medical center. METHODS: We enrolled 126 sarcoidosis subjects and 64 healthy controls and recorded baseline demographic and clinical characteristics. We used regression models to identify factors independently associated with pulmonary physiology. We tested whether blood transcript levels at study entry could relate to longitudinal changes in pulmonary physiology. RESULTS: White, non-Hispanics composed ~70% of subjects. Hispanics and Blacks had a diagnostic biopsy at an age ~7 years younger than whites. Obstructive, but not restrictive, physiology characterized Scadding Stage IV patients. Subjects reporting use of immunosuppression had worse FEV1%p, FVC%p, and DLCO%p compared to subjects never treated, regardless of Scadding stage. We defined sarcoidosis disease activity by a drop in pulmonary function over 36 months and found that subjects meeting this definition had significant repression of blood gene transcripts related to T cell receptor signaling pathways, referred to as the "TCR factor." CONCLUSION: Obstructive pulmonary physiology defined Stage IV patients which were mostly white, non-Hispanics. Genes comprising the composite gene expression score, TCR factor, may represent a blood-derived measure of T-cell activity and an indirect measure of active sarcoidosis inflammation. Validation of this measure could translate into individualized treatment for sarcoidosis patients.
INTRODUCTION:Sarcoidosis is a systemic inflammatory disease characterized by non-necrotizing granulomas in involved organs, most commonly the lung. Description of patient characteristics in the Western United States is limited. Furthermore, blood-based measures that relate to clinical sarcoidosis phenotypes are lacking. We present an analysis of a prospective, longitudinal sarcoidosis cohort at a Northern Californian academic medical center. METHODS: We enrolled 126 sarcoidosis subjects and 64 healthy controls and recorded baseline demographic and clinical characteristics. We used regression models to identify factors independently associated with pulmonary physiology. We tested whether blood transcript levels at study entry could relate to longitudinal changes in pulmonary physiology. RESULTS: White, non-Hispanics composed ~70% of subjects. Hispanics and Blacks had a diagnostic biopsy at an age ~7 years younger than whites. Obstructive, but not restrictive, physiology characterized Scadding Stage IV patients. Subjects reporting use of immunosuppression had worse FEV1%p, FVC%p, and DLCO%p compared to subjects never treated, regardless of Scadding stage. We defined sarcoidosis disease activity by a drop in pulmonary function over 36 months and found that subjects meeting this definition had significant repression of blood gene transcripts related to T cell receptor signaling pathways, referred to as the "TCR factor." CONCLUSION: Obstructive pulmonary physiology defined Stage IV patients which were mostly white, non-Hispanics. Genes comprising the composite gene expression score, TCR factor, may represent a blood-derived measure of T-cell activity and an indirect measure of active sarcoidosis inflammation. Validation of this measure could translate into individualized treatment for sarcoidosispatients.
Entities:
Keywords:
Gene expression; Obstructive lung disease; Sarcoidosis; T cell
Authors: Natalia V Rivera; Marcus Ronninger; Klementy Shchetynsky; Andre Franke; Markus M Nöthen; Joachim Müller-Quernheim; Stefan Schreiber; Indra Adrianto; Bekir Karakaya; Coline H M van Moorsel; Zdenka Navratilova; Vitezslav Kolek; Benjamin A Rybicki; Michael C Iannuzzi; Martin Petrek; Jan C Grutters; Courtney Montgomery; Annegret Fischer; Anders Eklund; Leonid Padyukov; Johan Grunewald Journal: Am J Respir Crit Care Med Date: 2016-05-01 Impact factor: 21.405
Authors: K V Prasad; Y C Cai; M Raab; B Duckworth; L Cantley; S E Shoelson; C E Rudd Journal: Proc Natl Acad Sci U S A Date: 1994-03-29 Impact factor: 11.205
Authors: C A Lareau; C F DeWeese; I Adrianto; C J Lessard; P M Gaffney; M C Iannuzzi; B A Rybicki; A M Levin; C G Montgomery Journal: Genes Immun Date: 2017-03-09 Impact factor: 4.248
Authors: Nicholas K Arger; Melissa E Ho; Isabel E Allen; Bryan S Benn; Prescott G Woodruff; Laura L Koth Journal: Respir Med Date: 2019-11-20 Impact factor: 3.415
Authors: Nicholas K Arger; Siddharth Machiraju; Isabel E Allen; Prescott G Woodruff; Laura L Koth Journal: Front Immunol Date: 2020-07-22 Impact factor: 7.561
Authors: Hok Sreng Te; David M Perlman; Chetan Shenoy; Daniel J Steinberger; Rebecca J Cogswell; Henri Roukoz; Erik J Peterson; Lin Zhang; Tadashi L Allen; Maneesh Bhargava Journal: BMC Pulm Med Date: 2020-06-01 Impact factor: 3.317